{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:16:13Z","timestamp":1790727373307,"version":"4.1.0"},"reference-count":335,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Cancer gene therapy is attracting considerable attention as a new treatment method for overcoming intractable cancers. CAR-T cell therapy has already achieved remarkable results, particularly for hematological tumors. Because CAR-T cells can increase within the body, they have the advantage of requiring only a single administration. In addition, CAR-T cell therapy targeting the CD19 antigen has been established for relapsed or refractory disease in young people with CD19-positive acute B-cell leukemia (B-acute lymphoblastic leukemia, B-ALL) and diffuse large B-cell lymphoma (DLBCL). In addition to CAR-T cell therapy, oncolytic viruses represent a promising approach for cancer treatment, with some already in clinical use and others being researched for their potential benefits. These viruses infect and kill cancer cells, triggering an immune response that helps the body recognize and fight cancer. Oncolytic virus therapy is a form of immunotherapy that uses modified viruses to target and destroy tumor cells while potentially stimulating antitumor immune responses. These viruses have shown promising activity in clinical trials, with some approved for specific cancers like melanoma. Research is ongoing to improve their efficacy, expand their use to other cancer types, and overcome the logistical challenges associated with their delivery. Gene therapy can potentially treat diseases caused by recessive gene disorders like cystic fibrosis, hemophilia, muscular dystrophy, and sickle cell anemia, as well as acquired genetic diseases, such as cancer and viral infections like acquired immunodeficiency syndrome (AIDS).<\/jats:p>","DOI":"10.3390\/cimb47040268","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T05:28:07Z","timestamp":1744262887000},"page":"268","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups"],"prefix":"10.3390","volume":"47","author":[{"given":"Yasunari","family":"Matsuzaka","sequence":"first","affiliation":[{"name":"Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan"},{"name":"Administrative Section of Radiation Protection, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Yashiro","sequence":"additional","affiliation":[{"name":"Administrative Section of Radiation Protection, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan"},{"name":"Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.21037\/atm-22-3882","article-title":"A new era of gene and cell therapy for cancer: A narrative review","volume":"11","author":"Wang","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/ijgc-00009577-200409000-00004","article-title":"Prophylactic human papillomavirus vaccines: The beginning of the end of cervical cancer","volume":"14","author":"Tjalma","year":"2004","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2105\/AJPH.2007.131656","article-title":"The moral justification for a compulsory human papillomavirus vaccination program","volume":"99","author":"Balog","year":"2009","journal-title":"Am. J. Public Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/0971-6203.103601","article-title":"Why are we still in the 1950s regarding management of cancer of uterine cervix?","volume":"37","author":"Das","year":"2012","journal-title":"J. Med. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2023S126","DOI":"10.1590\/1806-9282.2023s126","article-title":"History of radiotherapy in the treatment of uterine cervix cancer: An overview","volume":"69","author":"Carvalho","year":"2023","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond Current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2022","journal-title":"Genes Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"F1015","DOI":"10.12688\/f1000research.8391.1","article-title":"Some vexations that challenge viral immunology","volume":"5","author":"Rouse","year":"2016","journal-title":"F1000Research"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","article-title":"An introduction to immunology and immunopathology","volume":"14","author":"Marshall","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hamad, A., Yusubalieva, G.M., Baklaushev, V.P., Chumakov, P.M., and Lipatova, A.V. (2023). Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies. Viruses, 15.","DOI":"10.3390\/v15020547"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12672-023-00769-1","article-title":"Clinical advances in oncolytic virus therapy for malignant glioma: A systematic review","volume":"14","author":"Jiang","year":"2023","journal-title":"Discov. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Asija, S., Chatterjee, A., Goda, J.S., Yadav, S., Chekuri, G., and Purwar, R. (2023). Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1118246"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: A phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"200239","DOI":"10.1016\/j.tvr.2022.200239","article-title":"Small DNA tumor viruses and human cancer: Preclinical models of virus infection and disease","volume":"14","author":"Spurgeon","year":"2022","journal-title":"Tumour Virus Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4161\/cbt.10.10.13923","article-title":"Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention","volume":"10","author":"Saha","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Blanchette, P., and Teodoro, J.G. (2023). A Renaissance for Oncolytic Adenoviruses?. Viruses, 15.","DOI":"10.3390\/v15020358"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","article-title":"High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus","volume":"64","author":"Anderson","year":"2004","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2174\/138920112800958896","article-title":"Attenuated oncolytic measles virus strains as cancer therapeutics","volume":"13","author":"Msaouel","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1089\/humc.2017.015","article-title":"Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV","volume":"28","author":"Naik","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.32607\/20758251-2015-7-2-6-16","article-title":"Mechanisms of Oncolysis by Paramyxovirus Sendai","volume":"7","author":"Matveeva","year":"2015","journal-title":"Acta Nat."},{"key":"ref_21","unstructured":"Naureen, Z., Malacarne, D., Anpilogov, K., Dautaj, A., Camilleri, G., Cecchin, S., Bressan, S., Casadei, A., Albion, E., and Sorrentino, E. (2020). Comparison between American and European legislation in the therapeutical and alimentary bacteriophage usage. Acta Biomed., 91."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cooper, C.J., Khan Mirzaei, M., and Nilsson, A.S. (2016). Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.01209"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/intimm\/dxab013","article-title":"Development of COVID-19 vaccines utilizing gene therapy technology","volume":"33","author":"Nakagami","year":"2021","journal-title":"Int. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/78638","article-title":"A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer","volume":"6","author":"Khuri","year":"2000","journal-title":"Nat. Med."},{"key":"ref_26","first-page":"555","article-title":"A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX015 with intravenous gemcitabine in unresectable pancreatic carcinoma","volume":"9","author":"Hecht","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.cgt.7700585","article-title":"Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients","volume":"10","author":"Nemunaitis","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.gt.3302436","article-title":"Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas","volume":"12","author":"Galanis","year":"2005","journal-title":"Gene Ther."},{"key":"ref_29","first-page":"1666","article-title":"Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus","volume":"23","author":"Xia","year":"2004","journal-title":"Ai Zheng"},{"key":"ref_30","first-page":"7497","article-title":"Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high risk prostate cancer","volume":"63","author":"Freytag","year":"2003","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors\u2014An evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J. Immunother. Cancer."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-10-0196","article-title":"Phase I\/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III\/IV squamous cell cancer of the head and neck","volume":"16","author":"Harrington","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase I trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Markert","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-11-2181","article-title":"Phase I\/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies","volume":"18","author":"Karapangiotou","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.drudis.2021.04.020","article-title":"The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects","volume":"26","author":"Qiu","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2176\/nmc.ra.2020-0049","article-title":"Historic Overview of Genetic Engineering Technologies for Human Gene Therapy","volume":"60","author":"Tamura","year":"2020","journal-title":"Neurol. Med. Chir."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3906\/sag-2005-327","article-title":"Immune gene therapy of cancer","volume":"50","author":"Akbulut","year":"2020","journal-title":"Turk. J. Med. Sci."},{"key":"ref_40","unstructured":"Khatami, F., Aghamir, Z.S., Jahanshahi, F., Feiz-Abadi, S.A., Birang, F., Khoshchehreh, M., Namazi Shabestari, A., and Aghamir, S.M.K. (2022). The Gene Manipulation and Cellular Immunotherapy Combination in the Treatment of Cancer. Iran. J. Biotechnol., 20."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhu, L., Zhang, H., Chen, S., and Xiao, Y. (2022). CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.927153"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Huang, J., Huang, X., and Huang, J. (2022). CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1019115"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Haslauer, T., Greil, R., Zaborsky, N., and Geisberger, R. (2021). CAR T-Cell Therapy in Hematological Malignancies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168996"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12943-024-02007-w","article-title":"Unveiling a novel fusion gene enhances CAR T cell therapy for solid tumors","volume":"23","author":"Zhou","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"eadk1857","DOI":"10.1126\/sciadv.adk1857","article-title":"TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors","volume":"10","author":"Nishimura","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Adhikarla, V., Awuah, D., Caserta, E., Minnix, M., Kuznetsov, M., Krishnan, A., Wong, J.Y.C., Shively, J.E., Wang, X., and Pichiorri, F. (2024). Designing combination therapies for cancer treatment: Application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1358478"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2338984","DOI":"10.1080\/21645515.2024.2338984","article-title":"Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012\u20132023)","volume":"20","author":"Miao","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e008555","DOI":"10.1136\/jitc-2023-008555","article-title":"Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system","volume":"12","author":"Khaniya","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1021\/acs.bioconjchem.4c00050","article-title":"Construction of Switch Modules for CAR-T Cell Treatment Using a Site-Specific Conjugation System","volume":"35","author":"Abudureheman","year":"2024","journal-title":"Bioconjug. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"107186","DOI":"10.1016\/j.phrs.2024.107186","article-title":"Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects","volume":"203","author":"Zhu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Pandit, S., Agarwalla, P., Song, F., Jansson, A., Dotti, G., and Brudno, Y. (2024). Implantable CAR T cell factories enhance solid tumor treatment. Biomaterials, 308.","DOI":"10.1016\/j.biomaterials.2024.122580"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00262-024-03685-7","article-title":"Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediatesantitumor activity in glioblastoma","volume":"73","author":"Sakunrangsit","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/CM9.0000000000003111","article-title":"Dawn of CAR-T cell therapy in autoimmune diseases","volume":"137","author":"Liu","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e008261","DOI":"10.1136\/jitc-2023-008261","article-title":"Armored TGFbetaRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFbeta1","volume":"12","author":"Tran","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Garc\u00eda, L.G., S\u00e1nchez, E., Ivanova, M., Pastora, K., Alc\u00e1ntara-S\u00e1nchez, C., Garc\u00eda-Mart\u00ednez, J., Mart\u00edn-Antonio, B., Ram\u00edrez, M., and Gonz\u00e1lez-Murillo, \u00c1. (2024). Choosing T-cell sources determines CAR-T cell activity in neuroblastoma. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1375833"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1158\/1078-0432.CCR-23-3690","article-title":"Applications and opportunities for immune cell CAR engineering in comparative oncology","volume":"30","author":"Rotolo","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13046-024-03027-6","article-title":"Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening","volume":"43","author":"Li","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41417-024-00752-0","article-title":"Gastrointestinal infections and gastrointestinal haemorrhage are underestimated but serious adverse events in chimeric antigen receptor T-cell recipients: A real-world study","volume":"31","author":"Song","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"100728","DOI":"10.1016\/j.crmeth.2024.100728","article-title":"An engineering strategy to target activated EGFR with CAR T cells","volume":"4","author":"Dobersberger","year":"2024","journal-title":"Cell Rep. Methods"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e007329","DOI":"10.1136\/jitc-2023-007329","article-title":"Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy","volume":"12","author":"Shishido","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"402.e1","DOI":"10.1016\/j.jtct.2024.01.069","article-title":"Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy","volume":"30","author":"Dhawale","year":"2024","journal-title":"Transplant. Cell Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e2302425","DOI":"10.1002\/adhm.202302425","article-title":"Engineering Improved CAR T Cell Products with A Multi-Cytokine Particle Platform for Hematologic and Solid Tumors","volume":"13","author":"Lin","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2174\/0115748928277331231218115402","article-title":"Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies","volume":"19","author":"Yangjie","year":"2024","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2643-3230.BCD-23-0056","article-title":"Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma","volume":"5","author":"Faramand","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtct.2023.12.011","article-title":"Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis","volume":"30","author":"Abid","year":"2024","journal-title":"Transplant. Cell Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11096-023-01670-1","article-title":"Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"46","author":"Zhang","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41231-023-00144-w","article-title":"Oncolytic virus-based suicide gene therapy for cancer treatment: A perspective of the clinical trials conducted at Henry Ford Health","volume":"8","author":"Thoidingjam","year":"2023","journal-title":"Transl. Med. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Ji, Q., Wu, Y., Albers, A., Fang, M., and Qian, X. (2022). Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091811"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41587-021-01191-0","article-title":"Expanding global access to genetic therapies","volume":"40","author":"Muigai","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2105\/AJPH.2023.307315","article-title":"CRISPR in Public Health: The Health Equity Implications and Role of Community in Gene-Editing Research and Applications","volume":"113","author":"Subica","year":"2023","journal-title":"Am. J. Public Health"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/pcmedi\/pbab014","article-title":"Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics","volume":"4","author":"Liu","year":"2021","journal-title":"Precis. Clin. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e3550","DOI":"10.1002\/jgm.3550","article-title":"Gene therapy in cancer","volume":"25","year":"2023","journal-title":"J. Gene Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Abudoureyimu, M., Lai, Y., Tian, C., Wang, T., Wang, R., and Chu, X. (2019). Oncolytic Adenovirus-A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01182"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e004167","DOI":"10.1136\/jitc-2021-004167","article-title":"Remodeling the tumor microenvironment by oncolytic viruses: Beyond oncolysis of tumor cells for cancer treatment","volume":"10","author":"Wang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Zhang, B., Wang, X., and Cheng, P. (2021). Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.561372"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/cgt.2015.11","article-title":"Oncolytic viruses: Focusing on the tumor microenvironment","volume":"22","author":"Kaufman","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-3-319-67577-0_11","article-title":"Oncolytic Virotherapy and the Tumor Microenvironment","volume":"1036","author":"Berkey","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e004935","DOI":"10.1136\/jitc-2022-004935","article-title":"Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry","volume":"10","author":"Nguyen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40425-018-0366-2","article-title":"Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference","volume":"6","author":"Bastin","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-57362-1_1","article-title":"An Introduction to Virus Infections and Human Cancer","volume":"217","author":"Schiller","year":"2021","journal-title":"Recent Results Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.omto.2020.10.011","article-title":"Decreasing the Susceptibility of Malignant Cells to Infection Does Not Impact the Overall Efficacy of Myxoma Virus-Based Oncolytic Virotherapy","volume":"19","author":"Flores","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/bs.mie.2019.05.017","article-title":"Genetic modification of oncolytic viruses to enhance antitumor immunity","volume":"635","author":"Davola","year":"2020","journal-title":"Methods Enzymol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Davola, M.E., Cormier, O., Vito, A., El-Sayes, N., Collins, S., Salem, O., Revill, S., Ask, K., Wan, Y., and Mossman, K. (2023). Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells. Cancers, 15.","DOI":"10.3390\/cancers15041295"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","article-title":"Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines","volume":"33","author":"Russell","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Rahman, M.M., and McFadden, G. (2021). Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13215452"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Russo, E., Laffranchi, M., Tomaipitinca, L., Del Prete, A., Santoni, A., Sozzani, S., and Bernardini, G. (2021). NK Cell Antitumor Surveillance in a Myeloid Cell-Shaped Environment. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.787116"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12964-023-01424-6","article-title":"Macrophage barrier in the tumor microenvironment and potential clinical applications","volume":"22","author":"Ji","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Salvi","year":"2023","journal-title":"Cell Mol. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Yang, Y.L., Yang, F., Huang, Z.Q., Li, Y.Y., Shi, H.Y., Sun, Q., Ma, Y., Wang, Y., Zhang, Y., and Yang, S. (2023). T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1199173"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00005-023-00683-y","article-title":"In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy","volume":"71","author":"Wojciechowska","year":"2023","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Ma, W., He, H., and Wang, H. (2018). Oncolytic herpes simplex virus and immunotherapy. BMC Immunol., 19.","DOI":"10.1186\/s12865-018-0281-9"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1358\/dof.2010.35.3.1470166","article-title":"Oncolytic Herpes Simplex Virus 1 (HSV-1) Vectors: Increasing Treatment Efficacy and Range Through Strategic Virus Design","volume":"35","author":"Carson","year":"2010","journal-title":"Drugs Future"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Tang, G., Wang, D., Zhao, X., Feng, Z., Chen, Q., and Shen, Y. (2023). The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043681"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Scanlan, H., Coffman, Z., Bettencourt, J., Shipley, T., and Bramblett, D.E. (2022). Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.940019"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omto.2020.03.022","article-title":"Efficacy of a Third-Generation Oncolytic Herpes Virus G47\u0394 in Advanced Stage Models of Human Gastric Cancer","volume":"17","author":"Sugawara","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cas.13492","article-title":"Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice","volume":"109","author":"Nakatake","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.omto.2022.04.010","article-title":"Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models","volume":"25","author":"Hatta","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_104","first-page":"19","article-title":"Gene editing: Towards the third generation of adoptive T-cell transfer therapies","volume":"1","author":"Ribas","year":"2019","journal-title":"Immunooncol. Technol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: Progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","article-title":"Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: Results of a pivotal trial","volume":"16","author":"Schubert","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Kumar, A., Taghi Khani, A., Sanchez Ortiz, A., and Swaminathan, S. (2022). GM-CSF: A Double-Edged Sword in Cancer Immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.901277"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Ferrucci, P.F., Pala, L., Conforti, F., and Cocorocchio, E. (2021). Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13061383"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12943-021-01374-y","article-title":"GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer\/T cell lymphoma","volume":"20","author":"Rong","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Tijtgat, J., De Munck, J., Dufait, I., Schwarze, J.K., Van Riet, I., Franceschini, L., Breckpot, K., Aerts, J.L., Neyns, B., and Tuyaerts, S. (2021). Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.733506"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/G47\u0394: First Approval","volume":"36","author":"Frampton","year":"2022","journal-title":"BioDrugs"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Ghouse, S.M., Nguyen, H.M., Bommareddy, P.K., Guz-Montgomery, K., and Saha, D. (2020). Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00384"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Nguyen, H.M., Guz-Montgomery, K., and Saha, D. (2020). Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy. Cells, 9.","DOI":"10.3390\/cells9020400"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s43856-023-00270-4","article-title":"Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12","volume":"3","author":"Fukuhara","year":"2023","journal-title":"Commun. Med."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Liu, X., Zhang, J., Feng, K., Wang, S., Chen, L., Niu, S., Lu, Q., and Fang, Y. (2022). Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1023533"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.21037\/tcr-21-905","article-title":"The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: A systematic review and meta-analysis","volume":"10","author":"Gao","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: A current review","volume":"10","year":"2021","journal-title":"World J. Virol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Benmebarek, M.R., Karches, C.H., Cadilha, B.L., Lesch, S., Endres, S., and Kobold, S. (2019). Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061283"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","article-title":"Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5483\/BMBRep.2021.54.1.257","article-title":"Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7","volume":"54","author":"Kim","year":"2021","journal-title":"BMB Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: A systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-19-3487","article-title":"Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells","volume":"26","author":"Ichikawa","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ymthe.2022.02.002","article-title":"The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease","volume":"30","author":"Hont","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/imcb.12538","article-title":"Rapid and efficient generation of antigen-specific isogenic T cells from cryopreserved blood samples","volume":"100","author":"Eerkens","year":"2022","journal-title":"Immunol. Cell Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.it.2022.09.007","article-title":"Reimagining antibody-dependent cellular cytotoxicity in cancer: The potential of natural killer cell engagers","volume":"43","author":"Pinto","year":"2022","journal-title":"Trends Immunol."},{"key":"ref_129","first-page":"85","article-title":"Assessment of chimeric antigen receptor T cytotoxicity by droplet microfluidics in vitro","volume":"5","author":"Wong","year":"2022","journal-title":"Antib. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"100920","DOI":"10.1016\/j.xpro.2021.100920","article-title":"In vitro evaluation of CAR-T cells in patient-derived glioblastoma models","volume":"2","author":"Brakel","year":"2021","journal-title":"STAR Protoc."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/s41596-020-00467-0","article-title":"Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity","volume":"16","author":"Kiesgen","year":"2021","journal-title":"Nat. Protoc."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Espie, D., and Donnadieu, E. (2022). New insights into CAR T cell-mediated killing of tumor cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1016208"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41467-020-20671-6","article-title":"Direct control of CAR T cells through small molecule-regulated antibodies","volume":"12","author":"Park","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Khan, A.N., Chowdhury, A., Karulkar, A., Jaiswal, A.K., Banik, A., Asija, S., and Purwar, R. (2022). Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.886546"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Ochi, T., Maruta, M., Tanimoto, K., Kondo, F., Yamamoto, T., Kurata, M., Fujiwara, H., Masumoto, J., Takenaka, K., and Yasukawa, M. (2021). A single-chain antibody generation system yielding CAR-T cells with superiorantitumor function. Commun. Biol., 4.","DOI":"10.1038\/s42003-021-01791-1"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1038\/s41375-021-01269-3","article-title":"Single VHH-directed BCMA CAR-T cells cause remission of relapsed\/refractory multiple myeloma","volume":"35","author":"Han","year":"2021","journal-title":"Leukemia"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Pomaznoy, M., Sethi, A., Greenbaum, J., and Peters, B. (2019). Identifying inaccuracies in gene expression estimates from unstranded RNA-seq data. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-52584-w"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.omto.2022.08.008","article-title":"A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers","volume":"26","author":"Birley","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","article-title":"Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector","volume":"26","author":"Smith","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Safarzadeh Kozani, P., Naseri, A., Mirarefin, S.M.J., Salem, F., Nikbakht, M., Evazi Bakhshi, S., and Safarzadeh Kozani, P. (2022). Nanobody-based CAR-T cells for cancer immunotherapy. Biomark. Res., 10.","DOI":"10.1186\/s40364-022-00371-7"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41423-020-0470-3","article-title":"Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells","volume":"17","author":"Wu","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and Design of Chimeric Antigen Receptors","volume":"12","author":"Guedan","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Daei Sorkhabi, A., Mohamed Khosroshahi, L., Sarkesh, A., Mardi, A., Aghebati-Maleki, A., Aghebati-Maleki, L., and Baradaran, B. (2023). The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1113882"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Tiruneh","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Zhu, Y.G., Xiao, B.F., Zhang, J.T., Cui, X.R., Lu, Z.M., and Wu, N. (2021). Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.763806"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Zhang, H., Zhu, S., Deng, W., Li, R., Zhou, H., and Xiong, H. (2022). The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.887471"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Tomasik, J., Jasi\u0144ski, M., and Basak, G.W. (2022). Next generations of CAR-T cells\u2014New therapeutic opportunities in hematology?. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1034707"},{"key":"ref_150","first-page":"24","article-title":"Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells","volume":"7","author":"Ueda","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1016\/j.ymthe.2021.05.016","article-title":"Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy","volume":"29","author":"Kawai","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Wakao, R., and Fukaya-Shiba, A. (2023). In vivo CAR T cells and targeted gene delivery: A theme for the Pharmaceuticals and Medical Devices Agency Science Board to address. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1141880"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ymthe.2019.03.012","article-title":"The Future: In Vivo CAR T Cell Gene Therapy","volume":"27","author":"Mhaidly","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Jogalekar, M.P., Rajendran, R.L., Khan, F., Dmello, C., Gangadaran, P., and Ahn, B.C. (2022). CAR T-Cell-Based gene therapy for cancers: New perspectives, challenges, and clinical developments. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.925985"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Mehrabadi, A.Z., Ranjbar, R., Farzanehpour, M., Shahriary, A., Dorostkar, R., Hamidinejad, M.A., and Ghaleh, H.E.G. (2022). Therapeutic potential of CAR T cell in malignancies: A scoping review. Biomed. Pharmacother., 146.","DOI":"10.1016\/j.biopha.2021.112512"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: Next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Dai, Q., Han, P., Qi, X., Li, F., Li, M., Fan, L., Zhang, H., Zhang, X., and Yang, X. (2020). 4-1BB Signaling Boosts the Antitumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.539654"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine Release Syndrome: Current Perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: Functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin. Transl. Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e1433518","DOI":"10.1080\/2162402X.2018.1433518","article-title":"Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma","volume":"7","author":"Quintarelli","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12967-023-04372-4","article-title":"Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality","volume":"21","author":"Smith","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Liu, Q., Liu, Z., Wan, R., and Huang, W. (2022). Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies. Cancers, 14.","DOI":"10.3390\/cancers14184452"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.omtm.2022.02.004","article-title":"Clinically relevant T cell expansion media activate distinct metabolic programs uncoupled from cellular function","volume":"24","author":"MacPherson","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Guan, X.Y., and Jiang, P. (2020). Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.594609"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Bell, M., and Gottschalk, S. (2021). Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.684642"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1002\/ijc.33523","article-title":"Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges","volume":"148","author":"Herda","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Waugh, R.E., Lomakina, E., Amitrano, A., and Kim, M. (2023). Activation effects on the physical characteristics of T lymphocytes. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1175570"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Liu, C., Qi, T., Milner, J.J., Lu, Y., and Cao, Y. (2021). Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.748768"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41551-023-01048-8","article-title":"Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR","volume":"7","author":"Zhang","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","article-title":"Genetically engineered T cells for cancer immunotherapy","volume":"4","author":"Li","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"eabn3353","DOI":"10.1126\/scitranslmed.abn3353","article-title":"B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?","volume":"14","author":"Chen","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12935-021-01763-9","article-title":"Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer","volume":"21","author":"Jin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Jayaraman, J., Mellody, M.P., Hou, A.J., Desai, R.P., Fung, A.W., Pham, A.H.T., Chen, Y.Y., and Zhao, W. (2020). CAR-T design: Elements and their synergistic function. EBioMedicine, 58.","DOI":"10.1016\/j.ebiom.2020.102931"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Jafarzadeh, L., Masoumi, E., Fallah-Mehrjardi, K., Mirzaei, H.R., and Hadjati, J. (2020). Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00702"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Cantillo, G., Urue\u00f1a, C., Camacho, B.A., and Ram\u00edrez-Segura, C. (2022). CAR-T Cell Performance: How to Improve Their Persistence?. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.878209"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-Generation CAR T-cell Therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/d41573-023-00140-7","article-title":"The next-generation CAR-T therapy landscape","volume":"22","author":"Verma","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: Design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2515135520927164","DOI":"10.1177\/2515135520927164","article-title":"CAR T-cell immunotherapy of B-cell malignancy: The story so far","volume":"8","author":"Halim","year":"2020","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Kleber, M., Ntanasis-Stathopoulos, I., and Terpos, E. (2021). BCMA in Multiple Myeloma-A Promising Key to Therapy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10184088"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","article-title":"TCR engineered T cells for solid tumor immunotherapy","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1093\/gerona\/glaa209","article-title":"Underlying Vulnerabilities to the Cytokine Storm and Adverse COVID-19 Outcomes in the Aging Immune System","volume":"76","author":"Nidadavolu","year":"2021","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Shah, D., Soper, B., and Shopland, L. (2023). Cytokine release syndrome and cancer immunotherapies\u2014Historical challenges and promising futures. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1190379"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Fugere, T., Baltz, A., Mukherjee, A., Gaddam, M., Varma, A., Veeraputhiran, M., and Gentille Sanchez, C.G. (2023). Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity. Cancers, 15.","DOI":"10.3390\/cancers15215149"},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Huo, Y., Sheng, Z., Lu, D.R., Ellwanger, D.C., Li, C.M., Homann, O., Wang, S., Yin, H., and Ren, R. (2021). Blinatumomab-induced T cell activation at single cell transcriptome resolution. BMC Genom., 22.","DOI":"10.1186\/s12864-021-07435-2"},{"key":"ref_193","first-page":"21","article-title":"CAR T-Cell Therapy: Adverse Events and Management","volume":"10","author":"Adkins","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Miao, L., Zhang, Z., Ren, Z., and Li, Y. (2021). Reactions Related to CAR-T Cell Therapy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.663201"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2147\/JBM.S281247","article-title":"Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma","volume":"12","author":"Chavez","year":"2021","journal-title":"J. Blood Med."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Sterner, R.C., and Sterner, R.M. (2022). Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.879608"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Baumeister, S.H.C., Mohan, G.S., Elhaddad, A., and Lehmann, L. (2022). Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.841117"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3324\/haematol.2022.281110","article-title":"Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy","volume":"108","author":"Berger","year":"2023","journal-title":"Haematologica"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1038\/s41409-021-01471-y","article-title":"Cell subsets and cytokine dynamics in cerebrospinal fluid after CAR-T cell therapy for B-cell acute lymphoblastic leukemia with central nervous system involvement","volume":"56","author":"Hu","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood.2021014630","article-title":"Hemophagocytosis in cerebrospinal fluid after CAR T-cell therapy","volume":"139","author":"Shah","year":"2022","journal-title":"Blood"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.3324\/haematol.2023.282875","article-title":"CAR T-cell therapy for central nervous system lymphomas: Blood and cerebrospinal fluid biology, and outcomes","volume":"108","author":"Lacan","year":"2023","journal-title":"Haematologica"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mdc3.13106","article-title":"Myoclonus-Ataxia Syndromes: A Diagnostic Approach","volume":"8","author":"Rossi","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3348\/kjr.2019.0303","article-title":"Acute Acquired Metabolic Encephalopathy Based on Diffusion MRI","volume":"22","author":"Jeon","year":"2021","journal-title":"Korean J. Radiol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11604-020-00989-3","article-title":"Comprehensive review of Wernicke encephalopathy: Pathophysiology, clinical symptoms and imaging findings","volume":"38","author":"Ota","year":"2020","journal-title":"Jpn. J. Radiol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1148\/rg.2019190016","article-title":"Imaging Patterns of Toxic and Metabolic Brain Disorders","volume":"39","author":"Paulino","year":"2019","journal-title":"Radiographics"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"577400","DOI":"10.1016\/j.jneuroim.2020.577400","article-title":"COVID-19-related encephalopathy presenting with aphasia resolving following tocilizumab treatment","volume":"349","author":"Muccioli","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/hematology.2019000018","article-title":"Mechanisms of and approaches to overcoming resistance to immunotherapy","volume":"2019","author":"Schultz","year":"2019","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","article-title":"Engineering enhanced CAR T-cells for improved cancer therapy","volume":"2","author":"Milone","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41588-023-01313-1","article-title":"Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors","volume":"55","author":"Zapata","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: Progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","article-title":"Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma","volume":"1","author":"Simon","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: A phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Penack, O., and Koenecke, C. (2020). Complications after CD19+ CAR T-Cell Therapy. Cancers, 12.","DOI":"10.3390\/cancers12113445"},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Wang, A.X., Ong, X.J., D\u2019Souza, C., Neeson, P.J., and Zhu, J.J. (2023). Combining chemotherapy with CAR-T cell therapy in treating solid tumors. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1140541"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: The next revolution in cancer treatment","volume":"22","author":"Tondok","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Choi, G., Shin, G., and Bae, S. (2022). Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph191912366"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"e397912","DOI":"10.1200\/EDBK_397912","article-title":"High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma","volume":"7","author":"Potnis","year":"2023","journal-title":"Blood Adv."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1182\/bloodadvances.2020003036","article-title":"CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: An intent-to-treat comparison","volume":"4","author":"Dreger","year":"2020","journal-title":"Blood Adv."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.bbmt.2020.04.003","article-title":"Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?","volume":"26","author":"Bouziana","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Zhao, Y.L., Liu, D.Y., Sun, R.J., Zhang, J.P., Zhou, J.R., Wei, Z.J., Xiong, M., Cao, X.Y., Lu, Y., and Yang, J.F. (2021). Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.605766"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"eabn2231","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41417-021-00359-9","article-title":"Combination therapy with CAR T cells and oncolytic viruses: A new era in cancer immunotherapy","volume":"29","author":"Rezaei","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Piersma, B., Hayward, M.K., and Weaver, V.M. (2020). Fibrosis and cancer: A strained relationship. Biochim. Biophys. Acta Rev. Cancer, 1873.","DOI":"10.1016\/j.bbcan.2020.188356"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.trsl.2019.02.006","article-title":"The double edge sword of fibrosis in cancer","volume":"209","author":"Chandler","year":"2019","journal-title":"Transl. Res."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12943-018-0927-5","article-title":"Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis","volume":"18","author":"Thomas","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1172\/JCI93554","article-title":"The fibrotic tumor stroma","volume":"128","author":"Yamauchi","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12964-022-01012-0","article-title":"Mesenchymal stem cell-released oncolytic virus: An innovative strategy for cancer treatment","volume":"21","author":"Gilmanova","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Mahasa, K.J., de Pillis, L., Ouifki, R., Eladdadi, A., Maini, P., Yoon, A.R., and Yun, C.O. (2020). Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy. Sci. Rep., 10.","DOI":"10.1038\/s41598-019-57240-x"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"172991","DOI":"10.1016\/j.ejphar.2020.172991","article-title":"Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses","volume":"874","author":"Sochanik","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omto.2022.09.004","article-title":"Enhanced tumor targeting and timely viral release of mesenchymal stem cells\/oncolytic virus complex due to GRP78 and inducible E1B55K expressions greatly increase the antitumor effect of systemic treatment","volume":"27","author":"Choi","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.omto.2022.03.008","article-title":"Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors","volume":"25","author":"Yoon","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/s12967-023-04709-z","article-title":"Improving the therapeutic efficacy of oncolytic viruses for cancer: Targeting macrophages","volume":"21","author":"Shen","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Ren, Y., Miao, J.M., Wang, Y.Y., Fan, Z., Kong, X.B., Yang, L., and Cheng, G. (2022). Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.961796"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1885778","DOI":"10.1080\/2162402X.2021.1885778","article-title":"Synergistic antitumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers","volume":"10","author":"Masemann","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Hwang, J.K., Hong, J., and Yun, C.O. (2020). Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228627"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","article-title":"Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds","volume":"13","author":"Sivanandam","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12943-022-01664-z","article-title":"Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., and Zhou, J. (2019). Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01237"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: Challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Zhu, X., Li, Q., and Zhu, X. (2022). Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.1034257"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1038\/s41467-022-32576-7","article-title":"In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions","volume":"13","author":"Nicolas","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s13311-020-00940-4","article-title":"Gene and Cell-Based Therapies for Parkinson\u2019s Disease: Where Are We?","volume":"17","author":"Buttery","year":"2020","journal-title":"Neurotherapeutics"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13045-022-01354-9","article-title":"Gene and cell therapies in China: Booming landscape under dual-track regulation","volume":"15","author":"Yin","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41434-020-0184-2","article-title":"Spotlight on gene therapy in China","volume":"27","author":"Ding","year":"2020","journal-title":"Gene Ther."},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Huang, H., Zhu, Q., Ga, M., Wu, D., Meng, X., Wang, S., Fang, H., Tang, Y., and Li, N. (2022). Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.930846"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2217\/fon-2022-0440","article-title":"Oncolytic viruses: Challenges and considerations in an evolving clinical landscape","volume":"18","author":"Lauer","year":"2022","journal-title":"Future Oncol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41434-023-00390-5","article-title":"Successes and challenges in clinical gene therapy","volume":"30","author":"Kohn","year":"2023","journal-title":"Gene Ther."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ymthe.2022.04.002","article-title":"Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India","volume":"30","author":"Cornetta","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.omtm.2020.10.004","article-title":"Clinical Development of Gene Therapies: The First Three Decades and Counting","volume":"19","author":"Lapteva","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.biotechadv.2017.12.013","article-title":"Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors","volume":"36","author":"Harrison","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.omtm.2021.02.010","article-title":"Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies","volume":"20","author":"Gimpel","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jcyt.2022.09.002","article-title":"Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma","volume":"24","author":"Thielen","year":"2022","journal-title":"Cytotherapy"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/01926233211003498","article-title":"Opinion on the Use of Animal Models in Nonclinical Safety Assessment: Pros and Cons","volume":"49","author":"Sura","year":"2021","journal-title":"Toxicol. Pathol."},{"key":"ref_266","first-page":"687","article-title":"Applications and developments of gene therapy drug delivery systems for genetic diseases","volume":"16","author":"Pan","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-020-19505-2","article-title":"The once and future gene therapy","volume":"11","author":"Bulaklak","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/cts.13270","article-title":"The economics of moonshots: Value in rare disease drug development","volume":"15","author":"Yates","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1754999","DOI":"10.1080\/19420862.2020.1754999","article-title":"Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D","volume":"12","author":"Farid","year":"2020","journal-title":"MAbs"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1089\/nat.2021.0048","article-title":"The Role of Patient Involvement When Developing Therapies","volume":"32","author":"Vroom","year":"2022","journal-title":"Nucleic Acid. Ther."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40900-022-00364-8","article-title":"Practices of patient engagement in drug development: A systematic scoping review","volume":"8","author":"Zvonareva","year":"2022","journal-title":"Res. Involv. Engag."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"ref_274","doi-asserted-by":"crossref","unstructured":"Brisse, M., Vrba, S.M., Kirk, N., Liang, Y., and Ly, H. (2020). Emerging Concepts and Technologies in Vaccine Development. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.583077"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2020.10.023","article-title":"Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment","volume":"29","author":"Watanabe","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.omtm.2018.03.002","article-title":"Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency","volume":"9","author":"Poletti","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In Vivo Gene Therapy","volume":"8","author":"Colella","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_279","doi-asserted-by":"crossref","unstructured":"Au, H.K.E., Isalan, M., and Mielcarek, M. (2022). Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. Front. Med., 8.","DOI":"10.3389\/fmed.2021.809118"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","article-title":"261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands","volume":"33","author":"Servais","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41417-021-00413-6","article-title":"Safety of Adeno-associated virus-based vector-mediated gene therapy-impact of vector dose","volume":"29","author":"Maurya","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Shen, W., Liu, S., and Ou, L. (2022). rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1001263"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1002\/cncr.33153","article-title":"Clinical implications of drug-induced liver injury in early-phase oncology clinical trials","volume":"126","author":"Mondaca","year":"2020","journal-title":"Cancer"},{"key":"ref_286","doi-asserted-by":"crossref","unstructured":"Li, Y., Glass, Z., Huang, M., Chen, Z.Y., and Xu, Q. (2020). Ex vivo cell-based CRISPR\/Cas9 genome editing for therapeutic applications. Biomaterials, 234.","DOI":"10.1016\/j.biomaterials.2019.119711"},{"key":"ref_287","doi-asserted-by":"crossref","unstructured":"Ho, B.X., Loh, S.J.H., Chan, W.K., and Soh, B.S. (2018). In Vivo Genome Editing as a Therapeutic Approach. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092721"},{"key":"ref_288","doi-asserted-by":"crossref","unstructured":"Lubroth, P., Colasante, G., and Lignani, G. (2021). In vivo Genome Editing Therapeutic Approaches for Neurological Disorders: Where Are We in the Translational Pipeline?. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.632522"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.apsb.2021.05.020","article-title":"In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges","volume":"11","author":"Behr","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41434-022-00375-w","article-title":"In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model","volume":"30","author":"Chen","year":"2023","journal-title":"Gene Ther."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"key":"ref_292","doi-asserted-by":"crossref","unstructured":"Deng, H.X., Zhai, H., Shi, Y., Liu, G., Lowry, J., Liu, B., Ryan, \u00c9.B., Yan, J., Yang, Y., and Zhang, N. (2021). Efficacy and long-term safety of CRISPR\/Cas9 genome editing in the SOD1-linked mouse models of ALS. Commun. Biol., 4.","DOI":"10.1038\/s42003-021-01942-4"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/exd.14314","article-title":"Ex vivo gene modification therapy for genetic skin diseases-recent advances in gene modification technologies and delivery","volume":"30","author":"Jayarajan","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_294","doi-asserted-by":"crossref","unstructured":"Colella, P., Meneghini, V., Baldo, G., and Gomez-Ospina, N. (2023). Ex-vivo and in-vivo genome engineering for metabolic and neurometabolic diseases. Front. Genome Ed., 5.","DOI":"10.3389\/fgeed.2023.1248904"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s12276-023-01057-2","article-title":"Genome editing in the treatment of ocular diseases","volume":"55","author":"Choi","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5599\/admet.1209","article-title":"New therapeutic modalities in drug discovery and development: Insights & opportunities","volume":"9","author":"Kansy","year":"2021","journal-title":"ADMET DMPK"},{"key":"ref_298","doi-asserted-by":"crossref","unstructured":"Landhuis, E. (2021). The Definition of Gene Therapy Has Changed. Nature.","DOI":"10.1038\/d41586-021-02736-8"},{"key":"ref_299","doi-asserted-by":"crossref","unstructured":"Banoun, H. (2023). mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues. Int. J. Mol. Sci., 24.","DOI":"10.32388\/WW4UEN.3"},{"key":"ref_300","doi-asserted-by":"crossref","unstructured":"Yuan, M., Webb, E., Lemoine, N.R., and Wang, Y. (2016). CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses. Viruses, 8.","DOI":"10.3390\/v8030072"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/bs.mie.2019.08.011","article-title":"Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR\/Cas9 genetic disruption","volume":"635","author":"Bommareddy","year":"2020","journal-title":"Methods Enzymol."},{"key":"ref_302","doi-asserted-by":"crossref","unstructured":"Wei, W., Chen, Z.N., and Wang, K. (2023). CRISPR\/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512317"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/hum.2020.310","article-title":"Advances in the Development and the Applications of Nonviral, Episomal Vectors for Gene Therapy","volume":"2","author":"Mulia","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s12967-022-03747-3","article-title":"Current strategies employed in the manipulation of gene expression for clinical purposes","volume":"20","author":"Tsai","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12033-023-00724-z","article-title":"An Update on the Application of CRISPR Technology in Clinical Practice","volume":"66","author":"Morshedzadeh","year":"2024","journal-title":"Mol. Biotechnol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_308","doi-asserted-by":"crossref","unstructured":"Ponterio, E., Haas, T.L., and De Maria, R. (2024). Oncolytic virus and CAR-T cell therapy in solid tumors. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1455163"},{"key":"ref_309","doi-asserted-by":"crossref","unstructured":"Wu, Y.Y., Sun, T.K., Chen, M.S., Munir, M., and Liu, H.J. (2023). Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response. Front. Cell Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1142172"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/hum.2020.278","article-title":"Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy","volume":"32","author":"McGrath","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd.2016.178","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"15","author":"Kaufman","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"e008608","DOI":"10.1136\/jitc-2023-008608","article-title":"Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis","volume":"12","author":"Ash","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_315","first-page":"1979","article-title":"Innovative strategies to advance CAR T cell therapy for solid tumors","volume":"10","author":"Huang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol. Immunol."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"e008429","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_318","doi-asserted-by":"crossref","unstructured":"Lv, Y., Luo, X., Xie, Z., Qiu, J., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., and Zuo, J. (2024). Prospects and challenges of CAR-T cell therapy combined with ICIs. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1368732"},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"ref_320","doi-asserted-by":"crossref","unstructured":"Rodriguez-Garcia, A., Palazon, A., Noguera-Ortega, E., Powell, D.J., and Guedan, S. (2020). CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01109"},{"key":"ref_321","doi-asserted-by":"crossref","unstructured":"Martinez, M., and Moon, E.K. (2019). CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00128"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_324","first-page":"1612","article-title":"Death but one unintended consequence of gene-therapy trial","volume":"164","author":"Sibbald","year":"2001","journal-title":"CMAJ"},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable Manufacturing of CAR T cells for Cancer Immunotherapy","volume":"2","author":"Elsallab","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ejh.14101","article-title":"Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions","volume":"112","author":"Mishra","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_328","doi-asserted-by":"crossref","unstructured":"Uddin, F., Rudin, C.M., and Sen, T. (2020). CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01387"},{"key":"ref_329","doi-asserted-by":"crossref","unstructured":"Levstek, L., Jan\u017ei\u010d, L., Ihan, A., and Kopitar, A.N. (2024). Biomarkers for prediction of CAR T therapy outcomes: Current and future perspectives. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1378944"},{"key":"ref_330","doi-asserted-by":"crossref","unstructured":"Ali, A., and DiPersio, J.F. (2024). ReCARving the future: Bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1432799"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic Viruses and the Immune System: The Dynamic Duo","volume":"17","author":"Franco","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_332","doi-asserted-by":"crossref","unstructured":"Marchini, A., Daeffler, L., Pozdeev, V.I., Angelova, A., and Rommelaere, J. (2019). Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01848"},{"key":"ref_333","doi-asserted-by":"crossref","unstructured":"Zhu, L., Lei, Y., Huang, J., An, Y., Ren, Y., Chen, L., Zhao, H., and Zheng, C. (2023). Recent advances in oncolytic virus therapy for hepatocellular carcinoma. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1172292"},{"key":"ref_334","doi-asserted-by":"crossref","unstructured":"Kooti, W., Esmaeili Gouvarchin Ghaleh, H., Farzanehpour, M., Dorostkar, R., Jalali Kondori, B., and Bolandian, M. (2021). Oncolytic Viruses and Cancer, Do You Know the Main Mechanism?. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.761015"},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41419-020-2696-5","article-title":"Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas","volume":"11","author":"Zhang","year":"2020","journal-title":"Cell Death Dis."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/4\/268\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:11:59Z","timestamp":1760029919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/4\/268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":335,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cimb47040268"],"URL":"https:\/\/doi.org\/10.3390\/cimb47040268","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}